Race Oncology Limited is thrilled to announce the appointment of Mr. Brendan Brown as its new Chief Financial Officer (CFO), effective from 1 April 2024. Mr. Brown, who is currently a Partner and Director at Prime Accounting & Business Advisory, part of the Prime Financial Group (ASX:PFG), is set to bring a wealth of experience to Race Oncology, having worked extensively with life science clients over the past 20 years.
A Chartered Accountant (CA ANZ) and Registered Tax Agent, Brendan Brown is equipped with a Bachelor of Commerce (Accounting) from La Trobe University. His comprehensive background in accounting and business advisory, particularly within the life sciences sector, positions him as an ideal leader to drive Race Oncology’s financial strategy and operations forward.
Brendan succeeds Ms. Christina Manfre of PKF Sydney Pty Ltd., who has made significant contributions to Race Oncology over the last two years. Race Oncology extends its gratitude to Ms. Manfre for her dedication and service, which have been instrumental in the company’s progress.
Dr. Daniel Tillett, CEO of Race Oncology, expressed his enthusiasm for Brendan’s appointment, highlighting the productive relationship Race has enjoyed with Prime over the last two years. Prime has been integral to Race’s success in R&D Tax Incentive claims, a key aspect of the company’s financial strategy. Dr. Tillett remarked, “We are pleased to be expanding our engagement with both Brendan and Prime as we advance our new formulation of bisantrene in the clinic in 2024.”
Brendan Brown’s appointment as CFO marks an exciting chapter for Race Oncology as it continues to develop and bring innovative cancer treatments to the forefront. With Brendan’s strategic financial oversight and Prime’s continued support, Race Oncology is well-positioned to achieve its goals and make significant strides in the life sciences sector.
